NewsBenzinga레이크프론트 바이오테라퓨틱스, 3분기 주당순손실 0.04유로로 예상치 0.19유로 상회, 매출 756만 9천 유로로 예상치 868만 유로 하회 레이크프론트 바이오테라퓨틱스, 3분기 주당순손실 0.04유로로 예상치 0.19유로 상회, 매출 756만 9천 유로로 예상치 868만 유로 하회 Benzinga 2026.11.11 21:13 (GMT+0) Open on Benzinga Other news StoneX Maintains Buy on Rivian Automotive, Lowers Price Target to $20 Amer Sports Unleashes $1 Billion Buyback, Raises 2026 Outlook EXCLUSIVE: Tesla Still Rules Leveraged ETFs, but Anthropic IPO and Micron’s Rise Signal What’s Next StoneX Reiterates Hold on iQIYIto Hold StoneX Maintains Buy on Baidu, Lowers Price Target to $125 Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide
Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide